In cases of emphysematous pyelonephritis caused by both a fungal pathogen and extensively drug‑resistant Escherichia coli, what is the recommended management?

Management of Emphysematous Pyelonephritis with Mixed Fungal and XDR E. coli Infection

In cases of emphysematous pyelonephritis caused by both fungal pathogens and extensively drug-resistant E. coli, immediate nephrectomy combined with aggressive antimicrobial therapy targeting both organisms is the recommended approach, as medical management alone frequently fails in this life-threatening scenario.

Immediate Surgical Intervention

Emphysematous pyelonephritis with mixed fungal-bacterial infection represents a surgical emergency. Nephrectomy should be performed urgently 1, 2, 3. The evidence is clear:

• Fungal emphysematous pyelonephritis has an indistinctive presentation and typically fails conservative management 4
• Even lower-class EPN can deteriorate despite antibiotics, drainage, and glycemic control when complicated by thrombocytopenia or acute kidney injury 5
• Case reports consistently demonstrate that initial medical therapy and percutaneous nephrostomy fail in fungal EPN, ultimately requiring nephrectomy 4
• The unpredictable clinical course of sequential fungal-bacterial infection leads to catastrophic outcomes even after initial improvement 6

Percutaneous nephrostomy drainage may be attempted initially only in patients who are too unstable for immediate surgery, but prepare for definitive nephrectomy as drainage alone is insufficient 3, 7.

Antimicrobial Therapy

For the Fungal Component:

Initiate amphotericin B deoxycholate 0.5-0.7 mg/kg daily immediately 1, 2. Alternative options include:

• Liposomal amphotericin B 3-5 mg/kg daily (preferred if renal impairment present) 1, 8
• Echinocandins (caspofungin 70mg loading, then 50mg daily; or micafungin 100mg daily) for azole-resistant species 1, 8

Add flucytosine 25 mg/kg four times daily if the Candida species is susceptible, as combination therapy with amphotericin B shows synergistic fungal killing 1, 2. Monitor flucytosine blood levels to minimize toxicity.

Do NOT use fluconazole as initial therapy in this critically ill patient, even if the organism appears susceptible 1, 2.

For the XDR E. coli Component:

Initiate intravenous polymyxin (colistin or polymyxin B) immediately 9, 10:

• Colistin: 300mg loading dose over 30-60 minutes, then 300-360mg divided in two doses daily
• Polymyxin B dosing per institutional protocol

Add combination therapy with one of the following based on susceptibility testing 9, 11:

1. Amikacin (preferred if susceptible): Aminoglycoside-containing regimens show 417 fewer clinical failures per 1000 patients 11. Amikacin demonstrates 100% susceptibility in recent EPN series 7

2. Cefoperazone-sulbactam or ampicillin-sulbactam (if available and susceptible): High-dose sulbactam (≥6g/day) combinations achieve higher clinical cure rates 11

3. Newer beta-lactam/beta-lactamase inhibitor combinations if susceptible:

   • Ceftazidime-avibactam 2.5g IV q8h over 3 hours 9
   • Meropenem-vaborbactam 4g IV q8h over 3 hours 9

Do NOT use tigecycline monotherapy - it has inadequate serum and urinary concentrations for bacteremia and urinary tract infections 9, 11.

Critical Management Points

Glycemic Control

Achieve strict blood glucose control immediately - uncontrolled diabetes is the primary risk factor and contributes to treatment failure 6, 4, 12, 5.

Duration of Therapy

• Continue antifungal therapy for minimum 2 weeks after nephrectomy 1, 2
• Continue antibacterial therapy for 7-14 days adjusted to clinical response 3, 7
• Consider lifelong suppressive oral azole therapy (fluconazole 200-400mg daily) after completing initial antifungal treatment if the patient survives 1, 13

Monitoring Requirements

• Perform therapeutic drug monitoring for aminoglycosides if available 11
• Monitor for nephrotoxicity and ototoxicity with aminoglycoside use 11
• Avoid combining multiple nephrotoxic agents (polymyxin + aminoglycoside) unless absolutely necessary 11
• Monitor flucytosine blood levels to prevent toxicity 1

Common Pitfalls to Avoid

1. Delaying surgery: Medical management alone has an 18% mortality rate in standard EPN 12 and is even higher with fungal involvement 6, 4

2. Using fluconazole initially: This is inadequate for critically ill patients with fungal EPN 1, 2

3. Monotherapy for either organism: Both require combination therapy in this severe presentation 9, 11

4. Assuming initial improvement means cure: Sequential fungal-bacterial infection has an unpredictable course with sudden deterioration even after apparent recovery 6

5. Inadequate source control: Percutaneous drainage without nephrectomy typically fails in fungal EPN 4, 12

The mortality rate remains extremely high despite aggressive intervention 6, 12, making early recognition and immediate combined medical-surgical management absolutely critical for survival.